<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00025584</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02422</org_study_id>
    <secondary_id>ID00-308</secondary_id>
    <secondary_id>N01CM17003</secondary_id>
    <secondary_id>CDR0000068976</secondary_id>
    <nct_id>NCT00025584</nct_id>
  </id_info>
  <brief_title>PS-341 in Treating Women With Metastatic Breast Cancer</brief_title>
  <official_title>Phase II Trial Of PS-341 In Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      PS-341 may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell&#xD;
      growth. Phase II trial to study the effectiveness of PS-341 in treating women who have&#xD;
      metastatic breast cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the efficacy of PS-341, in terms of response rate, in women with metastatic&#xD;
      breast cancer.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the clinical activity of this drug, in terms of progression-free survival, in&#xD;
      these women.&#xD;
&#xD;
      II. Determine the toxicity profile and tolerability of this drug in these women.&#xD;
&#xD;
      III. Determine the pharmacodynamics of this drug in these women.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive PS-341 IV over 3-5 seconds twice weekly on weeks 1 and 2. Courses repeat&#xD;
      every 3 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 12-35 patients will be accrued for this study within 9-12&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2001</start_date>
  <primary_completion_date type="Actual">August 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective tumor response (CR + PR)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>The agent would be of definite interest for further investigation if the associated response rate is at least 30% (p1), and would not be of further interest if the response rate is below 10% (p0).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Will be reported using the Kaplan-Meier method with 95% confidence intervals indicated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Will be reported using the Kaplan-Meier method with 95% confidence intervals indicated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between variations in the serum levels of adhesion molecules and angiogenic factors</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Will be evaluated and descriptive analysis will be performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tissue markers of biological activity</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Will be described in case of lesions amenable to tissue biopsy. The plasma pharmacodynamics of PS-341 as measured by the 20S-proteosome assay, will be used to measured the biological activity of the drug and correlated with response to treatment and variations in biomarkers.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Recurrent Breast Cancer</condition>
  <condition>Stage IV Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (bortezomib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive PS-341 IV over 3-5 seconds twice weekly on weeks 1 and 2. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (bortezomib)</arm_group_label>
    <other_name>LDP 341</other_name>
    <other_name>MLN341</other_name>
    <other_name>VELCADE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (bortezomib)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed invasive breast cancer&#xD;
&#xD;
               -  Clinical and/or radiological evidence of stage IV disease&#xD;
&#xD;
          -  Relapsed or resistant disease within 6-12 months after completion of prior&#xD;
             chemotherapy with doxorubicin or epirubicin and/or paclitaxel or docetaxel foradvanced&#xD;
             disease or in the adjuvant setting&#xD;
&#xD;
          -  At least 1 unidimensionally measurable lesion&#xD;
&#xD;
               -  At least 20 mm by conventional techniques&#xD;
&#xD;
               -  At least 10 mm by spiral CT scan&#xD;
&#xD;
               -  No bone metastases as only measurable site&#xD;
&#xD;
               -  Pleural or peritoneal effusions not acceptable as measurable disease&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Estrogen receptor-negative&#xD;
&#xD;
               -  Estrogen receptor-positive&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  Performance status - ECOG 0-2&#xD;
&#xD;
          -  Performance status - Karnofsky 60-100%&#xD;
&#xD;
          -  More than 12 weeks&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  AST or ALT no greater than 2.5 times upper limit of normal&#xD;
&#xD;
          -  Creatinine normal&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
          -  No acute ischemia or significant conduction abnormality by EKG&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  LVEF greater than 50%&#xD;
&#xD;
          -  No uncontrolled concurrent illness&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No prior allergic reaction(s) to compounds of similar chemical or biologic composition&#xD;
             to PS-341&#xD;
&#xD;
          -  No other malignancy within the past 5 years except carcinoma in situ of the cervix or&#xD;
             basal cell skin cancer&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective barrier-method contraception&#xD;
&#xD;
          -  See Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No more than 1 prior chemotherapy regimen for metastatic disease&#xD;
&#xD;
               -  High-dose regimen or bone marrow transplantation considered 1 prior regimen&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and&#xD;
             recovered&#xD;
&#xD;
          -  Prior hormonal therapy for metastatic disease or in adjuvant setting allowed&#xD;
&#xD;
          -  Prior localized radiotherapy allowed if it does not influence the signal evaluable&#xD;
             lesion&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  At least 2 weeks since prior minor surgery and recovered&#xD;
&#xD;
          -  At least 4 weeks since prior major surgery and recovered&#xD;
&#xD;
          -  No other concurrent investigational agent&#xD;
&#xD;
          -  No other concurrent investigational or commercial agents or therapies to treat this&#xD;
             malignancy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Massimo Cristofanilli</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>October 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 22, 2013</last_update_submitted>
  <last_update_submitted_qc>January 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

